FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.
Scott Gottlieb, the Trump administration's choice to be US FDA Commissioner, has his fingers in a lot of medical-product company pies.
Gottlieb was selected by the president to head the US regulatory agency in early March and will go before the Senate Health, Education, Labor, and Pensions Committee for his Senate...
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
